Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.62 |
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.56 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.56 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.56 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.56 |
| ▸ | CA5A | P35218 | 1/20 | 0.54 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.54 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.54 |
| ▸ | AHCY | P23526 | 3/20 | 0.51 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.48 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3053788 | 0.88 | NT5E (0.65) | NT5ELMNAHIF1AADORA3ADORA2A | |
| SCHEMBL2047557 | 0.88 | NT5E (0.65) | NT5ELMNAHIF1AADORA3ADORA2A | |
| SCHEMBL23474154 | 0.87 | NT5E (0.67) | NT5ELMNAHIF1AADORA3ADORA2A | |
| SCHEMBL23474181 | 0.87 | NT5E (0.67) | NT5ELMNAHIF1AADORA3ADORA2A | |
| SCHEMBL10684436 | 0.87 | NT5E (0.67) | NT5ELMNAHIF1AADORA3ADORA2A | |
| SCHEMBL5362967 | 0.86 | NT5E (0.65) | NT5ELMNAHIF1AADORA3ADORA2A | |
| SCHEMBL101380 | 0.84 | AHCY (0.62) | LMNAHIF1AADORA3ADORA2AADORA2B | |
| SCHEMBL3836258 | 0.82 | CA5A (0.63) | NT5ELMNAHIF1AADORA3ADORA2A | |
| SCHEMBL2406009 | 0.81 | ADORA3 (0.74) | NT5ELMNAHIF1AADORA3ADORA2A | |
| SCHEMBL23884966 | 0.81 | ADORA3 (0.74) | NT5ELMNAHIF1AADORA3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7189706-B2 | C2,5′-disubstituted and N6,C2,5′-trisubstituted adenosine derivatives and pharmaceutical compositions containing them | UNIVERSITEIT LEIDEN (NL) | 2007-03-13 | — | — | US | claimed |
| US-20040127452-A1 | C2,5'-disubstituted and N6,C2,5'-trisubstituted adenosine derivatives and pharmaceutical compositions containing them | UNIVERSITEIT LEIDEN (NL) | 2004-07-01 | — | — | US | claimed |
| US-7189706-B2 | C2,5′-disubstituted and N6,C2,5′-trisubstituted adenosine derivatives and pharmaceutical compositions containing them | UNIVERSITEIT LEIDEN (NL) | 2007-03-13 | — | — | US | disclosed |
| US-20040127452-A1 | C2,5'-disubstituted and N6,C2,5'-trisubstituted adenosine derivatives and pharmaceutical compositions containing them | UNIVERSITEIT LEIDEN (NL) | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127452-A1 | C2,5'-disubstituted and N6,C2,5'-trisubstituted adenosine derivatives and pharmaceutical compositions containing them | ADORA2A, ADORA3, ADORA1 | NT5E 27/4885LMNA 1971/4885HIF1A 1019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.